Temozolomide | Enzo Life Sciences ALX-420-044-M025 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

Enzo Life Sciences

other brands :

Stressgen, BioMol, Alexis Corporation, Assay Designs, Alexis

product type :

chemical

product name :

Temozolomide

catalog :

ALX-420-044-M025

quantity :

25 mg

citations: 10

Reference
Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist. 2007;12:1114-23 pubmed
Addeo R, Caraglia M, Faiola V, Capasso E, Vincenzi B, Montella L, et al. Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life. BMC Cancer. 2007;7:18 pubmed
Geiger H, Schleimer D, Nattamai K, Dannenmann S, Davies S, WEISS B. Mutagenic potential of temozolomide in bone marrow cells in vivo. Blood. 2006;107:3010-1 pubmed
Kurzen H, Schmitt S, Näher H, Möhler T. Inhibition of angiogenesis by non-toxic doses of temozolomide. Anticancer Drugs. 2003;14:515-22 pubmed
Gunther W, Pawlak E, Damasceno R, Arnold H, Terzis A. Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids. Br J Cancer. 2003;88:463-9 pubmed
Danson S, Middleton M. Temozolomide: a novel oral alkylating agent. Expert Rev Anticancer Ther. 2001;1:13-9 pubmed
Tentori L, Leonetti C, Scarsella M, D Amati G, Portarena I, Zupi G, et al. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood. 2002;99:2241-4 pubmed
Wang Y, Stevens M, Chan Tm T, DiBenedetto D, Ding Zx Z, Gala D, et al. Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide. J Org Chem. 1997;62:7288-7294 pubmed
Hirose Y, Berger M, Pieper R. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res. 2001;61:1957-63 pubmed
Newlands E, Stevens M, Wedge S, Wheelhouse R, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1997;23:35-61 pubmed

product information

Product ID :

ALX-420-044

Catalog Number :

ALX-420-044-M025

Product Name :

Temozolomide

Product Type :

Biochemical

Size :

25 mg

list of Pubmed id :

17914081, 17254350, 16554488, 12960735, 12569392, 12113120, 11877304, 11671842, 11280752, 9189180

Product Description :

Antitumor and antiangiogenic compound. DNA alkylating agent. Induces G2/M arrest and apoptosis through adduction of a methyl group to O6 position of guanine in genomic DNA. Inactivates DNA repair protein O(6)-alkylguanine DNA alkyltransferase (AGT) in base excision repair (BER) pathway. Chemotherapeutic agent. Modifies drug resistance.

ALTnames :

8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one

Purity :

≥98% (Assay)

Storage :

-20°C